DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

February 8, 2024

Clinical Trial for Patients with Primary Central Nervous System Lymphoma (PCNSL)

Ono Pharma is actively recruiting patients with Primary Central Nervous System Lymphoma (PCNSL) for the PROSPECT Study. PROSPECT is an open-label, Phase II study evaluating the evaluating the efficacy, safety, and pharmacokinetics of an investigational oral medicine called Tirabrutinib, a Bruton’s Tyrosine Kinase inhibitor.

Prospect Ono logo

Current treatment options for PCNSL are limited, and there are no medications approved specifically for the treatment of PCNSL in the United States. New treatment options are needed to improve the prognosis for those with PCNSL. The PROSPECT study is a clinical trial to evaluate an investigational oral medicine called Tirabrutinib in patients with PCNSL. About 112 participants will be enrolled in the Phase II PROSPECT study in the United States.


Shreya Prakash photo

Contact Shreya Prakash
Clinical Research Coordinator
& Patient Navigator
shreya@endbraincancer.org

425-436-8688

contact QR code

Scan or click QR code to reach EBCI's Clinical Research Coordinator.


Hand holding cell phone displaying app
  • Trials & Studies
  • New Research
  • Patient & Caregiver Resources
  • Disease Information
  • Meetings & Events
  • And More!
EBCI App QR

Scan or click the QR code to download the App now!


Sponsors jan 2024

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram